首站-论文投稿智能助手
典型文献
Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
文献摘要:
Bromodomain containing protein 4(BRD4),as an epigenetic reader,can specifically bind to the acetyl lysine residues of histones and has emerged as an attractive therapeutic target for various diseases,including cancer,cardiac remodeling and heart failure.Herein,we described the discovery of hit 5 bearing 4-phenylquinazoline skeleton through a high-throughput virtual screen using 2,003,400 compound library(enamine).Then,structure-activity relationship(SAR)study was performed and 47 new 4-phenylquinazoline derivatives toward BRD4 were further designed,synthesized and evaluated,using HTRF assay set up in our lab.Eventually,we identified compound C-34,which possessed better pharmacokinetic and physicochemical properties as well as lower cytotoxicity against NRCF and NRCM cells,compared to the pos-itive control JQ1.Using computer-based molecular docking and cellular thermal shift assay,we further verified that C-34 could target BRD4 at molecular and cellular levels.Furthermore,treatment with C-34 effectively alleviated fibroblast activation in vitro and cardiac fibrosis in vivo,which was correlated with the decreased expression of BRD4 downstream target c-MYC as well as the depressed TGF-β1/Smad2/3 signaling pathway.Taken together,our findings indicate that novel BRD4 inhibitor C-34 tethering a 4-phenylquinazoline scaffold can serve as a lead compound for further development to treat fibrotic cardiovascular disease.
文献关键词:
作者姓名:
Zhangxu He;Haomiao Jiao;Qi An;Xin Zhang;Dan Zengyangzong;Jiale Xu;Hongmin Liu;Liying Ma;Wen Zhao
作者机构:
State Key Laboratory of Esophageal Cancer Prevention and Treatment,Key Laboratory of Advanced Pharmaceutical Technology,Ministry of Education of China,School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China;China Meheco Topfond Pharmaceutical Co.,Zhumadian 463000,China
引用格式:
[1]Zhangxu He;Haomiao Jiao;Qi An;Xin Zhang;Dan Zengyangzong;Jiale Xu;Hongmin Liu;Liying Ma;Wen Zhao-.Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis)[J].药学学报(英文版),2022(01):291-307
A类:
phenylquinazoline,enamine,NRCF,NRCM
B类:
Discovery,novel,BRD4,inhibitors,cardiac,fibrosis,Bromodomain,containing,protein,epigenetic,reader,specifically,bind,acetyl,lysine,residues,histones,has,emerged,attractive,therapeutic,target,various,diseases,including,cancer,remodeling,heart,failure,Herein,described,discovery,hit,bearing,skeleton,high,throughput,virtual,screen,using,compound,library,Then,structure,activity,relationship,SAR,study,was,performed,new,derivatives,toward,were,further,designed,synthesized,evaluated,HTRF,assay,set,up,our,lab,Eventually,identified,which,possessed,better,pharmacokinetic,physicochemical,properties,well,lower,cytotoxicity,against,cells,compared,itive,control,JQ1,Using,computer,molecular,docking,cellular,thermal,shift,verified,that,could,levels,Furthermore,treatment,effectively,alleviated,fibroblast,activation,vitro,vivo,correlated,decreased,expression,downstream,MYC,depressed,TGF,Smad2,signaling,pathway,Taken,together,findings,indicate,tethering,scaffold,serve,lead,development,fibrotic,cardiovascular
AB值:
0.644559
相似文献
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-αinduced by urotensin Ⅱ
Jun LI;Limin LUO;Yonggang ZHANG;Xiao DONG;Shuyi DANG;Xiaogang GUO;Wenhui DING-Department of Cardiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Division of Cardiology,Department of Internal Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China;Division of Cardiology,Department of Internal Medicine,Peking University First Hospital,Beijing 100034,China;Department of Dermatology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Cardiovascular Diseases,the Second Affiliated Hospital,Shantou University Medical College,Shantou 515041,China
Deubiquitinase ubiquitin-specific protease 3 (USP3) inhibits HIV-1 replication via promoting APOBEC3G (A3G) expression in both enzyme activity-dependent and -independent manners
Zhao Simin;Zheng Baisong;Wang Liuli;Cui Wenzhe;Jiang Chunlai;Li Zhuo;Gao Wenying;Zhang Wenyan-Center for Pathogen Biology and Infectious Diseases, Institute of Virology and AIDS Research, Key Laboratory of Organ Regeneration and Transplantation of The Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin 130021, China;College of Life Science of Jilin University, Changchun, Jilin 130012, China;Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130012, China;Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin 130041, China;Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, China
Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2
Ya-li Zhang;Wen-xin Zhang;Jue-qian Yan;Ye-lin Tang;Wen-jing Jia;Zheng-wei Xu;Ming-jiang Xu;Nipon Chattipakorn;Yi Wang;Jian-peng Feng;Zhi-guo Liu;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Yantai University,Yantai 264005,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Zhuji Biomedicine Institute,School of Pharmaceutical Sciences,Wenzhou Medical University,Zhuji 311800,China;Cardiac Electrophysiology Research and Training Center,Faculty of Medicine,Chiang Mai University,Chiang Mai 50200,Thailand;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou;Xiao Li;Li-ping Liao;Jie Han;Jing Huang;Jia-cheng Li;Hong-ru Tao;Shi-jie Fan;Zhi-feng Chen;Qi Li;Shi-jie Chen;Hong Ding;Ya-xi Yang;Bing Zhou;Hua-liang Jiang;Kai-xian Chen;Yuan-yuan Zhang;Chuan-xin Huang;Cheng Luo-Drug Discovery and Design Center,The Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China;Department of Medicinal Chemistry,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shanghai Institute of Immunology and Department of Immunology and Microbiology,Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,Faculty of Basic Medicine,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction
Hai-yan Wang;Pian Yu;Xi-sha Chen;Hui Wei;Shi-jie Cao;Meng Zhang;Yi Zhang;Yong-guang Tao;Dong-sheng Cao;Feng Qiu;Yan Cheng-Department of Pharmacy,The Second Xiangya Hospital,Central South University,Changsha 410011,China;Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug,Changsha 410011,China;Xiangya School of Pharmaceutical Sciences,Central South University,Changsha 410008,China;School of Chinese Materia Medica and Tianjin State Key Laboratory of Modern Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Department of Pharmacology,College of Pharmaceutical Sciences,Soochow University,Suzhou 215031,China;Key laboratory of Carcinogenesis and Cancer Invasion,Ministry of Education,Department of Pathology,Xiangya Hospital,School of Basic Medicine,Central South University,Changsha 410078,China;NHC Key laboratory of Carcinogenesis,Cancer Research Institute,Central South University,Changsha 410078,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway
Shuai-xing Wang;Ye-nan Feng;Shan Feng;Ji-min Wu;Mi Zhang;Wen-li Xu;You-yi Zhang;Hai-bo Zhu;Han Xiao;Er-dan Dong-Department of Cardiology and Institute of Vascular Medicine,Peking University Third Hospital,NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides,Key Laboratory of Molecular Cardiovascular Science,Ministry of Education,Beijing Key Laboratory of Cardiovascular Receptors Research,Beijing 100191,China;State Key Laboratory for Bioactive Substances and Functions of Natural Medicines,Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Design,synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl)sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia
Mao-feng Zhang;Xiao-yu Luo;Cheng Zhang;Chao Wang;Xi-shan Wu;Qiu-ping Xiang;Yong Xu;Yan Zhang-College of Pharmacy,Taizhou Polytechnic College,Taizhou 225300,China;Guangzhou Younan Technology Co.,Ltd,Guangzhou 510663,China;Center for Chemical Biology and Drug Discovery,Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou 510530,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Respiratory Disease,Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou 510530,China;China-New Zealand Joint Laboratory on Biomedicine and Health,Guangzhou 510530,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。